TransMedics (TMDX) Research & Development (2018 - 2026)

TransMedics has reported Research & Development for 9 years, with the latest figure at $31.6 million in Q2 2026.

• On a quarterly basis, Research & Development rose 98.52% year-over-year to $31.6 million in Q2 2026; TTM through Jun 2026 was $92.5 million, a 44.89% increase from a year earlier, with the FY2025 full-year figure at $69.1 million, up 23.38% from the prior year.
• Research & Development was $31.6 million for Q2 2026 at TransMedics, up from $24.9 million in the prior quarter.
• The five-year high for Research & Development was $31.6 million in Q2 2026, with the low at $5.8 million in Q4 2022.
• Average Research & Development over 5 years is $13.6 million, with a median of $12.6 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Research & Development slipped 22.07% in 2023, then surged 98.52% in 2026.
• Over 5 years, Research & Development stood at $5.8 million in 2022, then jumped by 86.95% to $10.8 million in 2023, then surged by 53.0% to $16.5 million in 2024, then grew by 25.73% to $20.7 million in 2025, then surged by 52.8% to $31.6 million in 2026.
• The last three Research & Development figures came in at $31.6 million (Q2 2026), $24.9 million (Q1 2026), and $20.7 million (Q4 2025), per Business Quant data.